Loading...
XBRU
IBAB
Market cap513mUSD
Sep 17, Last price  
15.26EUR
1D
0.00%
1Q
-7.18%
Jan 2017
-63.35%
Name

Ion Beam Applications SA

Chart & performance

D1W1MN
XBRU:IBAB chart
P/E
35.24
P/S
0.72
EPS
0.43
Div yield, %
1.57%
Shrs. gr., 5y
-0.12%
Rev. gr., 5y
14.73%
Revenues
620m
+24.49%
170,257,000213,849,000332,607,000332,607,000387,591,000237,694,000221,106,000212,512,000220,577,000270,357,000328,774,000236,485,000257,407,000282,552,000311,955,000312,964,000361,270,000428,717,000498,200,000620,200,000
Net income
13m
+36.56%
30,007,00013,846,0005,329,0005,329,0006,643,000-84,128,000-5,800,000-4,098,00024,294,00061,189,00024,440,000-41,658,000-4,401,0007,610,00031,921,0003,879,0006,057,000-9,110,0009,300,00012,700,000
CFO
-26m
L+157.00%
13,652,00018,034,00011,916,00011,916,00031,412,00038,268,000-30,736,0006,763,00014,969,00045,394,000-17,018,000-44,641,000-18,521,00045,893,000100,425,00085,010,00021,712,000-19,769,000-10,000,000-25,700,000
Dividend
Jun 15, 20260.25 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ion Beam Applications S.A. (IBA) is a company specializing in the design, manufacturing, and ongoing support of sophisticated medical equipment and software solutions primarily focused on treating cancer. Its operations span Belgium, the United States, and various international markets. The company's activities are broadly organized into two main divisions: 1. Proton Therapy and Other Accelerators: This segment is responsible for the engineering, construction, and maintenance of both medical and industrial particle accelerators, including complete proton therapy systems. It also delivers comprehensive, ready-to-use systems for cancer treatment leveraging proton beams. Furthermore, this division produces a variety of cyclotron machines for generating radioisotopes vital for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) imaging, alongside industrial-grade accelerators used in sterilization and ionization processes. 2. Dosimetry: This division offers specialized tools and expert services aimed at enhancing the precision and minimizing errors in radiation oncology treatments, as well as in the quality assurance and calibration protocols for medical imaging systems. IBA actively engages in strategic collaborations, including a key research and development partnership with SCK CEN (the Belgian nuclear research center) focused on enabling the synthesis of Actinium-225 (225Ac), a pioneering radioisotope for cancer therapy. The company also collaborates with the University of Pennsylvania for cutting-edge research into ConformalFLASH technology. Ion Beam Applications S.A. was established in 1986 and maintains its corporate headquarters in Louvain-la-Neuve, Belgium.

Related entities

Subsidiaries (2)
IBA Dosimetry GmbH
IBA INVESTMENTS

Key people

Berthold Baldus
President IBA Bioassays
Olivier Legrain
Chief Executive Officer, Managing Director, Inside Director · since 2012
Frederic Nolf
Chief Human Resource & Sustainability Officer, Member of the Management Board
Yves Jongen
Chief Research Officer, Managing Director, Inside Director, representing Technofutur SA · since 2000
Jean-Marc Bothy
Member of the Management Board, President of IBA Dosimetry · since 2018
Pierre Mottet
Chairman of the Board, Representing Saint-Denis SA · since 2013
Pierre Scalliet
Director · since 2012
Jeroen Cammeraat
Independent Director · since 2014
Hedvig Hricak
Independent Director · since 2017
Marcel Miller
Independent Director, Representing Consultance Marcel Miller SCS · since 2011
Sybille Van Den Hove
Independent Director, Representing Bridging for Sustainability SPRL · since 2018
Kathleen Vandeweyer
Independent Director, Representing Katleen Vandeweyer Comm. V. · since 2013
Yves Windelincx
Independent Director, representing Windi S.P.R.L. · since 2010
IPO date
Jun 13, 1998
Employees
2,000
Domiciled in
BE
Incorporated in
BE
Headquarters & legal address
Chemin du Cyclotron 3
Ottignies-Louvain-la-Neuve, WBR 1348
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT